CoChat

Safety of D(‐)‐Lactic Acid Producing Bacteria in the Human Infant

Connolly, Eamonn, Abrahamsson, Thomas, Björkstén, Bengt · 2005 · Journal of Pediatric Gastroenterology and Nutrition
Cited by 73

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

INTRODUCTION The gut of human infants is normally rapidly colonized after birth, and this colonization is considered not only to form a protective barrier against pathogenic bacteria but also to direct maturation of the infant immune system (1,2). In recent years, exogenous preparations of probiotic lactic acid bacteria have been administered to newborn infants in attempts to strengthen various positive effects associated with colonization with lactobacilli. Indeed, insufficient colonization with lactic acid producing bacteria in Western as compared with Eastern Europe may be associated with the increased incidence of allergy in the former countries (3,4). Furthermore, recent studies indicate that administration of probiotic lactobacilli to newborn infants (5) may be beneficial in directing maturation of the immune system. Concerns have been raised that the use of D(-)-lactic acid producing bacteria as probiotic ingredients in infants formulas may be harmful through a postulated increase in blood D(-)-lactic acid levels (6). There are no reports of any healthy humans of any age with abnormal D(-)-lactic acid levels, however, and certainly none arising as a result of the ingestion of D(-)-lactic acid producing bacteria (7,8). Lactobacillus reuteri ATCC 55730 (also called SD2112) is a proven probiotic with the capacity to reduce infections and diarrhea in infants (9-11), and it has been suggested that this probiotic may also have immunomodulatory effects against allergy. It is one of many species of Lactobacillus known to produce both L(+)-lactic acid and D(-)-lactic acid through normal sugar fermentation. Safety evaluations on L. reuteri ATCC 55730 have been performed in controlled clinical trials on healthy volunteers (12) and immunocompromised (HIV-infected) adults (13), children, and infants (10,11,14) without adverse effects. The present study investigates the levels of D(-)-lactic acid in the blood at the age of 6 and 12 months in infants who have been supplemented daily with the probiotic from birth. MATERIALS AND METHODS This study forms part of a double blind, placebo controlled, multicenter clinical trial in infants with a family history of allergy, conducted at the Departments of Paediatrics at the county hospitals of Jönköping, Motala and Norrköping and the University Hospital in Linköping, Sweden. The aims of this main study are related to the effect of exposure to L. reuteri on the development of allergic symptoms during the first year of life. The main study objectives are not related to the aims of the substudy we report here and will thus be reported separately when the study is complete. After receiving written consent from both parents, pregnant women from families with a history of allergic disease were enrolled and randomized to the L. reuteri or placebo groups. The infants were supplemented from birth with either L. reuteri ATCC 55730 suspended in an oil (75% refined MCT/25% protein-free peanut oil) or a placebo preparation identical in both appearance and taste but lacking the bacteria (BioGaia AB, Stockholm, Sweden). Both study products were produced by the sponsor of the trial and were supplied by their pharmacist blinded to the clinics. A dose of 1 × 108 colony forming units (CFU) or placebo was given (in 5 drops of oil) to the infants every day for 12 months starting from the first day of life. From the entire clinical trial (232 infants), a sample group of 24 infants was randomly chosen for the analysis of D(-)-lactic acid in the blood at 6 months of age (after 6 months of supplementation). Blood was drawn and frozen at −20°C before being shipped on dry ice for analysis of plasma D(-)-lactic acid content at the Centre for Inherited Metabolic Diseases, Karolinska University Hospital, (Stockholm, Sweden), using a validated and regularly used D(-)-lactic acid analytical method based on the method of Gawehn (15). The samples were extracted with perchloric acid before the assay. D-lactate was determined in the extracts with the enzyme D-lactate dehydrogenase (D-LDH), which is specific to the D-form of lactate. D-LDH converts D-lactate to pyruvate under the reduction of NAD+ to NADH. The amount of NADH formed was determined at 340 nm in a spectrophotometer and is proportional to the sample content of D-lactate. To ensure complete degradation of D-lactate, the assay was performed in the presence of the enzyme glutamate pyruvate transaminase, which continuously removes the pyruvate formed by D-LDH. Control samples containing 2 mmol/L D-lactate were also analyzed and gave adequate responses (coefficient of variation <3%). The main clinical trial is still blinded, and none of the investigators or the pharmacies at the trial sites has access to the code. To make the analysis of D(-)-lactic acid in the present study in each group, the patient codes and their corresponding analysis results were sent to an independent statistician at the University Hospital Linköping, Sweden for analysis indepen

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.mpg.0000176179.81638.45

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 73

Metadata

Authors
Connolly, E., Abrahamsson, T., & Björkstén, B.
Venue
Journal of Pediatric Gastroenterology and Nutrition
Publisher
Wiley
Published
2005-10
Volume
41
Issue
4
Pages
489-492
ISSN
  • 0277-2116 (ISSN-L)
  • 1536-4801
OpenAlex
W2035433950
Cited by
73
References
1
FWCI
3.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of D(‐)‐Lactic Acid Producing Bacteria in the Human Infant. https://app.cochat.ai/papers/10.1097/01.mpg.0000176179.81638.45
The paper
Connolly, E., Abrahamsson, T., & Björkstén, B. (2005). Safety of D(‐)‐Lactic Acid Producing Bacteria in the Human Infant. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1097/01.mpg.0000176179.81638.45

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.